BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 140 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,267,000 | -75.0% | 660,000 | -65.3% | 0.62% | -76.5% |
| Q2 2020 | $9,054,000 | +1710.8% | 1,900,000 | +660.0% | 2.62% | +981.0% |
| Q1 2020 | $500,000 | -94.9% | 250,000 | -91.2% | 0.24% | -90.0% |
| Q4 2019 | $9,746,000 | +4677.5% | 2,825,000 | +11200.0% | 2.41% | +2388.7% |
| Q1 2019 | $204,000 | +1.0% | 25,000 | 0.0% | 0.10% | -37.0% |
| Q4 2018 | $202,000 | -95.4% | 25,000 | -97.2% | 0.15% | -81.5% |
| Q4 2017 | $4,419,000 | -15.4% | 900,000 | -9.7% | 0.83% | -10.9% |
| Q3 2017 | $5,221,000 | +456.6% | 996,300 | +490.6% | 0.94% | +255.9% |
| Q2 2017 | $938,000 | -91.0% | 168,685 | -86.5% | 0.26% | -89.4% |
| Q1 2017 | $10,461,000 | +563.3% | 1,245,310 | +400.1% | 2.48% | +323.2% |
| Q4 2016 | $1,577,000 | -49.8% | 249,000 | -65.0% | 0.59% | -50.3% |
| Q3 2016 | $3,141,000 | +1.5% | 712,248 | +162.4% | 1.18% | -34.1% |
| Q3 2015 | $3,094,000 | – | 271,399 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |